Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.
Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant ...
Vepdegestrant (ARV-471) yielded a statistically significant and clinically meaningful improvement in progression-free ...
MedPage Today on MSN12d
Add-On Metformin Promising in ER-Positive Endometrial CancerAdding metformin to letrozole and abemaciclib (Verzenio) was tied to deep responses and prolonged progression-free survival ...
Topline results from the Phase III VERITAC-2 trial found that vepdegestrant provided a statistically significant and ...
Dr. Kevin Kalinsky covers the gamut of the current treatment landscape for patients with HER2-negative breast cancer, ...
“The results from SERENA-6 show that switching from an aromatase inhibitor to camizestrant in combination with any of the three CDK4/6 inhibitors after emergence of an ESR1 mutation delays progression ...
DelveInsight's "VERZENIO Market Size, Forecast, and Market Insight Report" highlights the details around VERZENIO, which is a targeted treatment known as a CDK4/6 inhibitor. The drug is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback